Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
ZBIO last changed hands at $27.83 (down 1.64%). At $1.81B, Zenas BioPharma is ranked #2853 by size among the 3132 stocks on BeStock.
Over a full year the shares have ranged across $13.50 to $44.60, which puts the current price roughly 46% of the way up that band. Holders are ahead 20.8% over twelve months, and up 0.5% across the last three months.
Price is below the 50-day average ($31.17) but above the 200-day ($25.23); RSI is 40, and the last 30 sessions moved at roughly 54% annualized volatility.
5 analysts follow the stock and the average call is "buy". The mean target, $44.80, sits 61.0% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 3131 U.S. stocks BeStock covers.
Trading closer to its 52-week high than most peers scores higher.
5 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
ZBIO is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $44.80, 61.0% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $21.16, so shares trade 31.5% above that estimate.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -7.6% | Bearish |
| Price vs 50-day average | -10.7% | Bearish |
| Price vs 200-day average | +10.3% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 40.1 | Bearish |
| MACD (12,26,9) | -1.10 | Bearish |
| Bollinger band position | 26% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 6, 2026 5:40 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,131 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$27.83 is the latest print for ZBIO, a move of -1.64% against yesterday's close of $28.30. Today's low and high so far: $27.77 and $29.06.
Equity value comes to $1.81B at the current price. By that measure it is number 2853 of the 3132 names in our coverage.
The year's floor is $13.50 and the ceiling $44.60. Shares are 37.6% away from that ceiling.
Our data shows no dividend paid by Zenas BioPharma over the trailing twelve months.
Of 5 analysts, 80% say buy, 20% hold and 0% sell. Price targets average $44.80, with the most cautious at $32.00 and the most optimistic at $55.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on ZBIO.